Tazorac — CareFirst (Caremark)

Initial criteria

• The requested drug is being prescribed for the topical treatment of acne vulgaris.

Reauthorization criteria

• The requested drug is being prescribed for the topical treatment of acne vulgaris AND the patient has achieved or maintained a positive clinical response as evidenced by improvement (e.g., reduction in number of lesions, etc.).

Approval duration

Initial: 4 months; Continuation: 36 months